Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On January 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the quarter and nine months ended December 31, 2024. The company reported a significant increase in revenues, with a 16% year-on-year growth for the quarter, aided by the acquisition of the NRT business and new product launches. Despite a slight decrease in gross margin, Dr. Reddy’s showed improved profitability and operational efficiencies. The results underscore the company’s commitment to growth through strategic acquisitions and innovation, positioning it favorably in the competitive pharmaceutical market.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. The company specializes in the development and manufacturing of generic medications, active pharmaceutical ingredients (APIs), and biological products, with a strong market focus on North America, Europe, India, and emerging markets.
YTD Price Performance: -5.55%
Average Trading Volume: 1,419,662
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.42B
For an in-depth examination of RDY stock, go to TipRanks’ Stock Analysis page.
